International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 ijppr.humanjournals.com ISSN: 2349-7203

Pembrolizumab: A Paradigm Shift in Cancer Immunotherapy

Ms. Gauri Narke*[1], Mr. Keshav Khadke[2], Mr. Krushna Khadke[3], Mr. Atharva Tilak[4], Mrs. Shraddha Dingare[5], Dr. Meera Deshmukh[6]

1. Lokmanya Tilak Institute of Pharmaceutical Sciences Pune 411037 India.

Received: 2025-04-24 Revised: 2025-05-05 Accepted: 2025-05-10

ABSTRACT

Pembrolizumab, a PD-1 resistant checkpoint inhibitor, has revolutionized cancer immunotherapy, illustrating viability over different malignancies, counting non-small cell lung cancer, melanoma, urothelial carcinoma, head and neck squamous cell carcinoma, and triple-negative breast cancer. Clinical trials have highlighted its prevalent survival benefits compared to ordinary chemotherapy, with eminent reaction rates in both first-line and headstrong settings. In spite of its promising results, pembrolizumab is related with immune-related antagonistic occasions, requiring cautious persistent choice and observing. Continuous investigate proceeds to refine its application, investigating combination treatments and prescient biomarkers to improve restorative adequacy.

Keywords: Pembrolizumab, Cancer Immunotherapy, PD-1 Inhibitor, Clinical Trials, Immune Checkpoint Blockade

INTRODUCTION

Cancer immunotherapy has changed oncology, with safe checkpoint inhibitors (ICIs) developing as a key helpful technique. Among them, pembrolizumab, a monoclonal counter acting agent focusing on the modified death-1 (PD-1) receptor, has illustrated critical viability over different malignancies, counting non-small cell lung cancer (NSCLC) [2,3,5], melanoma[6,8,9], urothelial carcinoma[12,15,24], head and neck squamous cell carcinoma [18,25], and triple-negative breast cancer[17]. By blocking the PD-1 pathway, pembrolizumab upgrades T-cell actuation, reestablishing anti-tumour insusceptibility[21]. Clinical trials have appeared pembrolizumab's prevalence over customary chemotherapy, with moved forward by and large survival and solid reactions in both first-line and hard-headed settings [2,3,7,19]. Its endorsement over numerous cancer sorts has driven to broad investigate investigating combination treatments with chemotherapy, radiotherapy, and other ICIs to upgrade restorative viability [4,10,11,22]. Be that as it may, pembrolizumab is related with immune-related antagonistic occasions, such as pneumonitis, colitis, and endocrinopathies, requiring watchful quiet choice and administration [1,13,19]. As the part of pembrolizumab proceeds to extend, continuous examinations centre on prescient biomarkers, such as PD-L1 expression and tumour mutational burden, to refine understanding determination and optimize treatment results [5,20,23]. This audit gives a comprehensive investigation of pembrolizumab's instrument of activity, clinical viability, security profile, and future headings in cancer immunotherapy.

Chemical and Pharmacological Properties

Pembrolizumab may be a humanized monoclonal counter acting agent that specifically targets modified passing receptor-1 (PD-1), a key safe checkpoint protein. It is an IgG4 kappa isotype counter acting agent, engineered to have decreased Fc receptor authoritative to play down antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC) (21). This includes guarantees that pembrolizumab essentially acts through safe balance instead of coordinate cytotoxicity. Atomic characteristics of pembrolizumab incorporate:

Atomic Weight: ~149 kDa [21]

Structure: Composed of two overwhelming chains and two light chains with variable and steady districts [21].

Component of Activity: Squares PD-1 intelligent with its ligands (PD-L1 and PD-L2), reestablishing T-cell actuation against cancer cells (21) Pharmacological Properties Instrument of Activity Pembrolizumab capacities as an safe checkpoint inhibitor, anticipating PD-1 from official to PD-L1 and PD-L2, which are regularly overexpressed in tumour microenvironments to sidestep safe location [10, 21]. This bar improves T-cell work, advancing an anti-tumour safe reaction [4, 6, 21].

Pharmacokinetics Assimilation: Managed by means of intravenous (IV) implantation, regularly over 30 minutes (4).

Dissemination: Shows a steady-state volume of conveyance (Vd) of ~6.0 L, showing restricted tissue conveyance past the vascular compartment [4, 10.]

Digestion system: Corrupted through proteolysis into little peptides and amino acids, comparable to other monoclonal antibodies [10, 21].

End: Half-life (tÃÂ½): Around 20 days [4, 10]

Clearance (CL): ~0.2 L/day, with direct pharmacokinetics at helpful measurements [4, 10]

Helpful Employments Pembrolizumab has appeared adequacy in different cancers, counting: Non-small cell lung cancer (NSCLC) [2, 3, 5, 20] Melanoma [6, 7, 8, 9] Bladder cancer [15, 24] Triple-negative breast cancer (TNBC) [17] Head and neck squamous cell carcinoma (HNSCC) [18, 25] Urothelial carcinoma [12] Haematological malignancies[16] Security and Antagonistic Impacts Whereas pembrolizumab is by and large well-tolerated, it can initiate immune-related antagonistic occasions (irAEs), counting:

Dermatological: Hasty, pruritus [7, 8]

Endocrine: Hypothyroidism, adrenal lacking [4, 10]

Gastrointestinal: Colitis, loose bowels [4, 7] Aspiratory

Pneumonitis [5, 10] Pembrolizumab has changed cancer immunotherapy by leveraging PD-1 hindrance to improve anti-tumour resistance. Its well-characterized pharmacokinetics, unsurprising clearance, and wide clinical adequacy make it a foundation of advanced oncology treatment procedures [4, 10, 21]. Be that as it may, cautious observing for immune-related unfavourable impacts remains basic for ideal persistent administration [4, 7, 10].

Therapeutic Applications

1. Non-Small Cell Lung Cancer (NSCLC)

Pembrolizumab is broadly utilized as a first-line or second-line treatment in NSCLC, particularly for tumours communicating PD-L1. A few clinical trials have illustrated its adequacy in making strides survival results compared to conventional chemotherapy [2,3,5,20]. It is especially viable in patients with PD-L1 expression 50% as a monotherapy and in combination with chemotherapy for lower PD-L1 expression cases [23]. Pembrolizumab monotherapy driven to noteworthy enhancement in by and large survival (OS) and progression-free survival (PFS) compared to platinum-based chemotherapy in PD-L1-positive tumours [3,23]. Combination treatment with chemotherapy appeared benefits in decreasing malady movement in advanced-stage NSCLC [5,20].

2. Progressed Melanoma

Pembrolizumab is FDA-approved for progressed melanoma treatment and has been a game-changer in immunotherapy. Thinks about have appeared its prevalence over chemotherapy and ipilimumab (CTLA-4 inhibitor) [6,8,9]. Pembrolizumab moves forward OS and PFS in melanoma compared to ipilimumab [9]. It upgrades anti-tumour resistant reactions by focusing on PD-1 receptors on T cells [6,8]. Tough reactions have been watched, making it a favoured first-line alternative [8].

3. Head and Neck Squamous Cell Carcinoma (HNSCC)

Pembrolizumab is utilized in repetitive or metastatic HNSCC, especially in PD-L1-positive cases [18,25]. It is frequently managed as monotherapy or in combination with chemotherapy. Prevalent to the Extraordinary regimen (platinum-based chemotherapy with cetuximab) in PD-L1-expressing tumours [18]. Made strides OS in treatment patients with repetitive or metastatic malady [25].

4. Bladder Cancer (Urothelial Carcinoma)

Pembrolizumab has been endorsed for patients with locally progressed or metastatic urothelial carcinoma who have advanced after platinum-based chemotherapy [12,15,24]. Illustrated survival benefits in patient's ineligible for cisplatin treatment [12]. Drawn out reaction rates compared to chemotherapy [15]. Utilized in both first-line and second-line settings [24].

5. Triple-Negative Breast Cancer (TNBC)

Pembrolizumab is picking up significance in treating PD-L1-positive TNBC, particularly in combination with chemotherapy. Critical advancement in OS and PFS when combined with chemotherapy in PD-L1-positive TNBC. Solid safe reaction driving to superior long-term illness control [17].

Safety and Adverse Effect

Security and Unfavourable Impacts of Pembrolizumab in Cancer Treatment Pembrolizumab, an anti-PD-1 monoclonal counter acting agent, has illustrated critical viability over different malignancies, but it utilizes is related with a range of immune-related unfavourable impacts (irAEs) and common toxicities.

1. Common Unfavourable Impacts:

Weakness, sickness, loose bowels, and hasty are as often as possible watched over different thinks about [1, 3, 7, 1]. - Infusion-related responses, counting fever and chills, may happen but are for the most part reasonable (11, 19).

2. Immune-Related Antagonistic Occasions (irAEs):

Dermatologic: Hasty and pruritus are among the foremost commonly detailed immune-related toxicities [7, 8, 10].

Gastrointestinal: Colitis and loose bowels can happen, now and then requiring immunosuppressive mediation [5, 12, 19].

Endocrine: Hypothyroidism and hyperthyroidism, together with adrenal inadequate, have been detailed [6, 9, 17].

Hepatic: Raised liver proteins and immune-mediated hepatitis, in spite of the fact that less visit, may require treatment cessation [15, 22].

Aspiratory: Pneumonitis, a genuine and possibly lethal side impact, has been watched in non-small-cell lung cancer (NSCLC) and melanoma patients [3, 13, 20].

Neurological: Uncommon cases of encephalitis and neuropathy have been archived 10, 24.

3. Serious and Life-Threatening Antagonistic Impacts: Review toxicities, in spite of the fact that less common, can incorporate extreme colitis, myocarditis, and nephritis [4, 18, 25]. Haematological impacts such as thrombocytopenia and frailty have been watched in a few considers [16, 23].

4. Administration Procedures: Unfavourable impacts are for the most part overseen through corticosteroids or other immunosuppressive treatments, with dosage alterations or treatment cessation in serious cases [9, 14, 21]. Near observing is fundamental, especially for patients with pre-existing immune system conditions or organ brokenness [2, 7, 19]. whereas pembrolizumab has revolutionized cancer immunotherapy, its security profile requires watchfulness due to the chance of genuine immune-related toxicities.

Formulation and Drug delivery system of Pembrolizumab

Definitions of Pembrolizumab Pembrolizumab could be a monoclonal counter acting agent focusing on modified death-1 (PD-1), which improves the safe reaction against tumours. It is accessible as: Intravenous (IV) Mixture (Keytruda) - The foremost broadly utilized definition. Accessible as a yophilized powder (100 mg) or a ready-to-use arrangement (25 mg/mL) [4, 7]. Requires weakening in 0.9% sodium chloride or 5% dextrose some time recently organization [10.]

Dose: 200 mg each 3 weeks or 400 mg each 6 weeks, depending on the cancer sort [6, 11].

1. Subcutaneous (SC) Definition (Beneath Improvement)

An unused SC detailing utilizing recombinant human hyaluronidase PH20 (rHuPH20) has been tried in Stage III clinical trials for lung cancer and melanoma [2, 18]. Decreases organization time from 30 minutes (IV) to minutes (SC) [11, 17]. Outlined to improve persistent comfort and decrease healing centre visits [5, 16].

International Journal of Pharmacy and Pharmaceutical Research (IJPPR)
Volume 31, Issue 6, June 2025 ijppr.humanjournals.com ISSN: 2349-7203

2. Medicate Conveyance Instruments

Pembrolizumab is conveyed utilizing parenteral courses due to its huge atomic weight and protein-based structure, which restrain verbal bioavailability. Intravenous Mixture (IV). The standard course for most immunotherapies [3, 8]. Guarantees 100% bioavailability and keeps up sedate levels over helpful limits [6, 15]. Requires therapeutic supervision due to immune-related antagonistic impacts (IRAEs) [9]. Subcutaneous (SC) Infusion (Future Elective) created to make strides persistent compliance and decrease infusion location responses [12, 22]. May modify pharmacokinetics (PK) by adjusting assimilation rate without compromising viability [24].

3. Challenges and Future Improvements Immunogenicity Dangers

Arrangement of anti-drug antibodies (ADAs) can decrease adequacy [14]. SC definitions may diminish ADA arrangement due to moderate retention [21].

4. Combination Treatments & Nanotechnology

Analysts are investigating nanoparticle-based pembrolizumab conveyance to move forward tumour focusing on [19, 23]. Combination with liposomal carriers or PEGylation seem improve bioavailability and soundness [25]. Pembrolizumab is as of now conveyed intravenously, with subcutaneous choices beneath clinical trials to upgrade persistent compliance. Future propels, counting nanoparticle-based conveyance and bioconjugation methodologies, may encourage move forward focusing on and diminish harmfulness.

Market and Economic Impact of Pembrolizumab

Advertise Affect

Pembrolizumab (Keytruda) has risen as a driving immunotherapy, essentially affecting the oncology sedate advertise. As of 2023, the worldwide pembrolizumab showcase was esteemed at around $19.5 billion, with projections showing development to $32.5 billion by 2031 at a CAGR of 6.5%[1]. The extension of signs over numerous cancer sorts, counting non-small cell lung cancer (NSCLC) [2, 3], melanoma 6, 8, urothelial carcinoma [12, 24], and triple-negative breast cancer [17], has driven its broad appropriation.

North America holds the biggest showcase share due to progressed healthcare framework and favourable repayment approaches [4, 5]. Be that as it may, the Asia-Pacific locale is encountering fast development due to expanding cancer predominance and progressing healthcare offices [7, 19].

Financial Affect

In spite of its clinical benefits, pembrolizumab presents financial challenges due to its tall taken a toll. Thinks about assessing its cost-effectiveness highlight concerns with respect to reasonableness in both created and creating healthcare frameworks [10, 11]. For case, in Thailand, an financial assessment surveyed the budget effect of pembrolizumab as a first-line monotherapy for NSCLC, affecting national model choices [5, 20].

Additionally, within the Joined together States, pembrolizumab□□s utilize in progressed cervical cancer (CPS â□¥1) has been analysed for cost-effectiveness, considering both coordinate therapeutic costs and societal efficiency picks up [9, 22]. The tall cost of pembrolizumab has driven to expanded examination with respect to its long-term effect on healthcare budgets [19, 25].

Future aspects and challenges

Future Viewpoints and Challenges of Pembrolizumab in Cancer Treatment

1. Extending Signs and Combination Treatments

Pembrolizumab has illustrated adequacy over different cancer sorts, counting non-small cell lung cancer (NSCLC), melanoma, urothelial carcinoma, and others [1, 4, 6, 12, 20]. Progressing investigate centres on extending it utilize in unused cancer subtypes, counting triple-negative breast cancer [17] and haematological malignancies [16]. Furthermore, combination treatments with chemotherapy, radiation, and other immunotherapies like CTLA-4 inhibitors appear guarantee in improving its viability [5, 9, 10].

2. Biomarkers and Understanding Determination

One of the key challenges is recognizing solid biomarkers to foresee reaction to pembrolizumab. Whereas PD-L1 expression may be a broadly utilized biomarker, its prescient precision remains variable [2, 5, 19] Tumour mutational burden (TMB) and microsatellite insecurity (MSI) are being investigated to refine understanding choice and make strides treatment results [3, 11].

3. Resistance Components and Treatment Disappointments

In spite of pembrolizumab victory, resistance both essential and obtained limits its long-term viability. Considers propose that safe elude components, such as T-cell fatigue and changes in tumour microenvironment, contribute to resistance[15,21]. Procedures like epigenetic balance and combining pembrolizumab with novel immunotherapies are being explored to overcome resistance[13, 22].

4. Financial and Availability Issues

The tall fetched of pembrolizumab remains a noteworthy challenge for healthcare frameworks universally. Cost-effectiveness investigations have been conducted to evaluate its financial burden, especially in resource-limited settings[14,19]. Endeavours to create biosimilars or elective dosing regimens seem offer assistance relieve budgetary imperatives and move forward availability[8, 23].

5. Long-Term Safety and Side Impacts

Whereas pembrolizumab encompasses a favourable security profile, immune-related antagonistic occasions (irAEs) such as pneumonitis, colitis, and endocrinopathies stay concerns [4, 7, 9]. Research is continuous to create prescient markers for irAEs and optimize administration methodologies to play down poisonous quality whereas keeping up viability[6, 18].

6. Future Clinical Trials and Personalized Pharmaceutical Progressing

Stage II and III trials are assessing pembrolizumab in combination with novel specialists, counting oncolytic infections and cancer antibodies, to improve resistant response[14, 21]. The integration of AI-driven exactness medication approaches is anticipated to make strides treatment personalization and optimize pembrolizumab-based regimens within the future[24, 25]. Pembrolizumab has brought a revolution in cancer immunotherapy, but challenges such as treatment resistance, costly therapies, and long-term security concerns have to be be tended to. Future inquires about focusing on biomarker-driven understanding determination, combination of treatments, profitable and cost-effective techniques will be important in maximizing its helpful potential.

Conclusion

Pembrolizumab functions as a game-changing immunotherapeutic treatment which produces better results in many cancers including non-small cell lung cancer and melanoma and urothelial carcinoma as well as head and "triple-negative breast cancer and neck squamous cell carcinoma. The PD-1 receptor targeting mechanism together with T-cell restoration has revolutionized therapy approaches to provide extended survival across multiple clinical scenarios. The success of pembrolizumab faces obstacles in the form of immune-related adverse events and resistance mechanisms along with substantial treatment expenses which create the requirement for detailed patient analysis and continuous safety monitoring together with cost-effectiveness evaluations. The road to success in cancer treatment requires biomarker-driven approaches together with combined drug treatments and alternative administration approaches that improve both effectiveness and patient access. The drug pembrolizumab serves as a key achievement and launchpad for upcoming cancer treatment developments that focus on individualized patient care.

REFERENCES

1. Baxi S, Yang A, Gennarelli RL, Khan N, Wang Z, Boyce L, et al. Immune-related adverse events for anti–PD-1 and anti–PD-L1 drugs: Systematic review and meta-analysis. *BMJ*. 2018;360: k793.
2. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, et al. Pembrolizumab for the treatment of non–small-cell lung cancer. *N Engl J Med*. 2015;372(21):2018–28.
3. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, et al. Pembrolizumab versus chemotherapy for PD-L1–positive non–small-cell lung cancer. *N Engl J Med*. 2016;375(19):1823–33.
4. KEYTRUDA (pembrolizumab) [prescribing information]. Whitehouse Station, NJ: Merck & Co., Inc.; 2023.
5. Herbst RS, Baas P, Kim D-W, Felip E, Pérez-Gracia JL, Han J-Y, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1–positive, advanced non–small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016;387(10027):1540–50.

6. Robert C, Schachter J, Long GV, Arance A, Grob J-J, Mortier L, et al. Pembrolizumab versus ipilimumab in advanced melanoma. *N Engl J Med*. 2015;372(26):2521–32.
7. Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab in untreated melanoma. *N Engl J Med*. 2016;375(19):1856–67.
8. Hamid O, Robert C, Daud A, Hodi FS, Hwu W-J, Kefford R, et al. Safety and tumour responses with lambrolizumab (anti–PD-1) in melanoma. *N Engl J Med*. 2013;369(2):134–44.
9. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, et al. Association of pembrolizumab with tumour response and survival among patients with advanced melanoma. *JAMA*. 2016;315(15):1600–9.
10. European Medicines Agency. *Assessment Report for Keytruda (Pembrolizumab)*. EMA; 2023.
11. Gandhi L, Rodríguez-Abreu D, Gadgeel S, Esteban E, Felip E, De Angelis F, et al. Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer. *N Engl J Med*. 2018;378(22):2078–92.
12. Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. *N Engl J Med*. 2017;376(11):1015–26.
13. Naidoo J, Wang X, Woo KM, Iyriboz T, Halpenny D, Cunningham J, et al. Pneumonitis in patients treated with anti–programmed death-1/programmed death ligand 1 therapy. *J Clin Oncol*. 2017;35(7):709–17.
14. Eggermont AMM, Chiarion-Sileni V, Grob J-J, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. *N Engl J Med*. 2018;378(19):1789–801.
15. Powles T, Duran I, van der Heijden MS, Loriot Y, Vogelzang NJ, De Giorgi U, et al. Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial. *Lancet*. 2018;391(10122):748–57.
16. Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and co-inhibition. *Nat Rev Immunol*. 2013;13(4):227–42.
17. Schmid P, Adams S, Rugo HS, Schneeweiss A, Barrios CH, Iwata H, et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. *N Engl J Med*. 2018;379(22):2108–21.
18. Cohen EEW, Soulières D, Le Tourneau C, Dinis J, Licitra L, Ahn M-J, et al. Pembrolizumab versus standard treatment for recurrent or metastatic head and neck squamous cell carcinoma: KEYNOTE-040. *Lancet*. 2019;393(10167):156–67.
19. Khozin S, Abernethy AP, Nussbaum NC, Zhi J, Curtis MD, McClellan M, et al. Characteristics of real-world metastatic non–small cell lung cancer patients treated with nivolumab and pembrolizumab during the year following approval. *Oncologist*. 2018;23(3):328–36.
20. Carbone DP, Reck M, Paz-Ares L, Creelan B, Horn L, Steins M, et al. First-line nivolumab in stage IV or recurrent non–small-cell lung cancer. *N Engl J Med*. 2017;376(25):2415–26.
21. Tan S, Li D, Zhu X. Cancer immunotherapy: Pros, cons and beyond. *Biomed Pharmacotherapy*. 2020;124:109821.
22. Slomovitz BM, Coleman RL. The PI3K/AKT/mTOR pathway as a therapeutic target in endometrial cancer. *Clin Cancer Res*. 2012;18(21):5856–64.
23. Garon EB, Hellmann MD, Rizvi NA, Carcereny E, Leighl NB, Ahn M-J, et al. Five-year overall survival for patients with advanced non–small-cell lung cancer treated with pembrolizumab: results from the phase I KEYNOTE-001 study. *J Clin Oncol*. 2019;37(28):2518–27.
24. Bajorin DF, Witjes JA, Gschwend JE, Oudard S, Retz M, Domingos J, et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. *N Engl J Med*. 2021;384(22):2102–14.
25. Burtness B, Harrington KJ, Greil R, Soulieres D, Tahara M, de Castro G, et al. Pembrolizumab alone or with chemotherapy vs cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomized, open-label, phase 3 study. *Lancet*. 2019;394(10212):1915–28.

How to cite this article:
Ms. Gauri Narke et al. Ijppr.Human, 2025; Vol. 31 (6): 140-145.
Conflict of Interest Statement: All authors have nothing else to disclose.